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ABSTRACT
Regulation of homologous recombination (HR)
represents the best-characterized DNA repair func-
tion of p53. The role of p53 phosphorylation in DNA
repair is largely unknown. Here, we show that wild-
type p53 repressed repair of DNA double-strand
breaks (DSBs) by HR in a manner partially requir-
ing the ATM/ATR phosphorylation site, serine 15.
Cdk-mediated phosphorylation of serine 315 was
dispensable for this anti-recombinogenic effect.
However, without targeted cleavage of the HR sub-
strate, serine 315 phosphorylation was necessary
for the activation of topoisomerase I-dependent
HR by p53. Moreover, overexpression of cyclin A1,
which mimics the situation in tumors, inappropri-
ately stimulated DSB-induced HR in the presence
of oncogenic p53 mutants (not Wtp53). This effect
required cyclin A1/cdk-mediated phosphorylation
for stable complex formation with topoisomerase I.
We conclude that p53 mutants have lost the balance
between activation and repression of HR, which
results in a net increase of potentially mutagenic
DNA rearrangements. Our data provide new insight
into the mechanism underlying gain-of-function of
mutant p53 in genomic instability.
INTRODUCTION
Because of the central role of p53 as a gatekeeper and a
caretaker, the protein must be subject to complex control
mechanisms that orchestrate the multiple functions of p53
in transcription, cell-cycle control, apoptosis induction
and DNA repair (1,2). Posttranslational modiﬁcation of
p53 by protein phosphorylation has been the most exten-
sively studied potential functional switch mechanism,
as it occurs at multiple serine and threonine residues in
response to genotoxic stress (3,4). Modiﬁcation of p53 on
serine 15 by ATM and ATR was demonstrated to trigger
the cascade of damage-induced phosphorylation and
acetylation events that have been implicated in protein
stabilization and enhancement of transcriptional transac-
tivation (3,4). However, observations made with knock-in
mouse models (5,6) indicated a role for serine 18 in apo-
ptosis, but not in Mdm2-governed protein stability. More-
over, in several studies, no evidence was found for an
essential role of the N-terminal casein kinase 1 (CK1)
and ATM/ATR phosphorylation sites in damage-induced
transcriptional transactivation (7–9). In addition, when
DNA replication was blocked, p53 became phosphory-
lated on serine 15, but this was not accompanied by
a rise in key target gene products such as p21 (10–12).
This suggested that after replication fork stalling, p53
phosphorylated on serine 15 (p53pSer15) may serve addi-
tional functions unrelated to transcriptional transactiva-
tion. In support of this hypothesis, colocalization studies
indicated that p53pSer15 forms a component of RAD51-
speciﬁc repair assemblies (11–13).
Over the last few years, a large body of evidence has
emerged indicating that p53 is directly involved in DNA
repair, particularly in homologous double-strand break
(DSB) repair. First, p53 recognizes three-stranded hetero-
duplex and four-way Holliday junctions and DNA lesions
involving mismatches, gaps or DNA ends. The core
domain is required for junction DNA-binding and also
harbors an exonuclease activity, the extreme C-terminus
stimulates these activities upon mismatch recognition
(2,14,15). Second, p53 physically and functionally inter-
acts with critical enzymes and surveillance factors of
homologous recombination (HR), namely with RAD51,
RAD54, the MRE11 complex, BRCA1, BRCA2 and
BLM, and counteracts strand exchange catalyzed by
RAD51. Third, using diﬀerent cell-based test systems,
several groups concurrently found that Wtp53 represses
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replication blocking agents. In contrast, hotspot mutants
failed to downregulate these HR activities. The identiﬁca-
tion of separation-of-function mutations, which had lost
p53’s transcriptional transactivation and cell-cycle regula-
tory capacity, but retained HR inhibition, and vice versa,
provided further evidence for p53’s direct role in HR con-
trol (2,14,15). A recent report describes transcriptional
repression of RAD51 by direct binding of Wtp53 to a
response element within the promoter region (16). This
mechanism can only partially explain the role of p53 in
HR, because mutations within the p53 interaction site of
the RAD51 protein abrogate HR repression by p53 (13).
Moreover, p53(138V), which is defective in sequence-
speciﬁc DNA binding, retains the HR-downregulatory
eﬀect (17). The biological meaning of this, at ﬁrst sight,
paradoxical activity directed against a fairly safe DNA
repair pathway was unveiled by systematic substrate
variation, which indicated a ﬁdelity control mechanism
directed against DNA exchange processes between diver-
gent sequences (in 15). Unexpectedly, Wtp53 was more
recently found to stimulate recombination in the absence
of targeted substrate cleavage in a manner depending on
topoisomerase I (topo I) (18,19). Spontaneous recombina-
tion events are coupled to the normal DNA metabolism
in proliferating cells such as during the bypass of low level,
endogenous lesions at replication forks, which are insuﬃ-
cient to activate stress signalling.
Upon exposure to ionizing radiation and generation
of highly recombinogenic DNA lesions such as DSBs,
the serines 6, 15 and 315 represent the most prominently
phosphorylated p53 residues (3). On the other hand,
Subramanian and Griﬃth (20) demonstrated that recogni-
tion of Holliday junction DNA by p53 is particularly sen-
sitive to posttranslational phosphorylation at serine 392
as compared to serines 6 or 15. To deﬁne the role of
phosphorylation in p53-dependent regulation of recombi-
native repair, we applied an EGFP-based recombination
assay in combination with cells expressing the correspond-
ing phosphorylation site mutants. Candidate kinases were
manipulated by pharmacological or shRNA-mediated
inhibition and by expression of regulatory subunits. We
ﬁnd that serine 15 phosphorylation by ATM/ATR is
one contributing mechanism to channel functions of p53
towards DSB repair surveillance. Serine 315 and cdk2 are
required for topo I-dependent recombination, which
involves dynamic interactions between p53 and topo I in
the nucleus. Together, our data indicate that site-speciﬁc
phosphorylation of p53 plays a critical role in the ﬁne-
tuning of repair pathways with important implications
for oncogenic p53 mutants.
MATERIAL AND METHODS
Cells and cell-cycle analysis
For HR-measurements KMV clones derived from the
human myeloid leukemia cell line K562 and KMV
(HR/30) derivatives with stably integrated HR-EGFP/
30EGFP substrate were raised in RPMI 1640 supplemented
with 10% FCS and 2mM L-glutamine (Biochrom, Berlin,
Germany) (21). Stable WTK1(HR/30) clones for measure-
ments of HR between HR-EGFP and 30EGFP on chromo-
somes were established from the lymphoblastoid cell line
WTK1 (21) and cultivated in RPMI 1640 with 12% FCS
and 3mM L-glutamine. When using pSVp53her expression
plasmids, cells were propagated in estradiol-free medium
before transfection and, then, cultivated in the presence of
estradiol ataﬁnalconcentration of 200nM tofully activate
the p53 moiety within the fusion protein of 90kD (21).
For the analysis of cell-cycle phases and apoptosis
induction at the time point of HR measurement, cells
were collected by centrifugation, resuspended in 1ml
HBSS (25mM HEPES, pH 7.4; 173.3mM NaCl;
5.6mM KCl; 0.44mM KH2PO4; 0.34mM Na2HPO4;
5mM glucose; 4mM NaHCO3) and ﬁxed in 10ml ﬁxing
solution (50% acetone; 40% ethanol; 10% ddH2O; at
 208C) on ice for 15min. For subsequent staining, ﬁxed
cells were washed with 2.5ml ice-cold PBS supplemented
with 0.2% EDTA, resuspended in 100ml propidium
iodide staining solution (0.25mg/ml RNAse A; 50mg/ml
propidium iodide from Sigma in PBS) and incubated for
15min in the dark. After diluting the suspension by 200ml
PBS with 0.2% EDTA, the stained cells were analyzed in
a FACS Calibur ﬂow cytometer (Becton Dickinson,
Heidelberg, Germany). The percentage of cells with sub-
G1 DNA content, which is indicative of apoptosis, was
determined, and viable cells were subdivided into popula-
tions in the cell-cycle phases G1, S and G2.
Plasmids
The following plasmids were previously described:
pSUPER-TopoI (19), pSUPER-p53 (22), pcDNA3-cyclin
A1 and pCMV-cyclin A2 (23), SMRAD51 chimera expres-
sion plasmid pcDNA3.1-Rad51SM (24), pKEX expression
constructs for rat p53 (7), pCMV-I-SceI, pCMV-Wtp53,
pCMV-p53(248W), pSVp53her and pSVp53(1-333)her
(21). pCMV-p53(315A) was constructed from pCMV-p53
(BDBiosciences Clontech, Heidelberg, Germany) byuse of
Quickchange (Stratagene Europe, Amsterdam, The
Netherlands) to introduce the point mutation. pKD-
cdk2-v5, pKD-E2F-1-v1 and empty vectors were pur-
chased from Upstate. Plasmid pSUPER-WRN directs the
synthesis of siRNA, which had previously been demon-
strated to speciﬁcally target WRN-mRNA (25).
pSUPER-WRN was generated as described for pSUPER-
TopoI in Baumann et al. (19) by use of the following oli-






newly created pSV53(15A) her for the expression of
p53her fusion protein mutated at serine 15 using PCR.
PCR ampliﬁcation relied on pSV53her template and the
primer 50-CTGGTACCATGGAGGAGCCGCAGTCAG
ATCCTAGCGTCGAGCCCCCTCTGGCTCAGGAAA
CATTTTCAGACC-30, covering the 50-end of the p53
cDNA (mutating bases underlined), and 50-AGATGG
CCATGGCGCGGACGCGG-30, covering an internal
Nucleic Acids Research, 2008, Vol. 36, No. 16 5363NcoI restriction site. The NcoI digested PCR product was
inserted into the pUC-subcloned XbaI fragment from
pSV53her, which was retransferred into pSV53her after
mutagenesis. The complete sequence encoding
p53(15A)her was veriﬁed by use of the ABi PRISM Big
Dye Ready Reaction Cycle Sequencing kit and an ABi
377 sequencer.
Antibody probes
We used the following mAbs: DO1 directed against
the N-terminus of p53, C21 against topo I, B88-2 against
cyclin A1, BD611168 against WRN and SX118 against p21
from Becton Dickinson, Pab421 against the C-terminus
of p53 (Calbiochem, Darmstadt, Germany), 1D6 against
topo I (Novocastra Laboratories Ltd, Newcastle upon
Tyne, UK ), E 67.1 recognizing Cyclin A2 from Cell
Signaling, FPS315 against p53pSer315 (MoBiTec/MBL,
Go ¨ ttingen, Germany) and KH20&KH95 against E2F1
(Upstate Biotechnology Incorporated, Lake Placid, NY,
USA). For immunodetection of rat p53, we used rabbit
serum NCL-p53-CM5p from Novocastra, for RAD51H-
92, for cyclin A1H-230 from Santa Cruz Biotechnology,
Santa Cruz, CA, USA and for cdk2 07-631 from Upstate.
For western analyses of actin, we applied the aﬃnity-pur-
iﬁed goat polyclonal antibody I-19 from Santa Cruz, for
tubulin mAb DM1A, for TBP mAb 1TBP18 and for
GAPDH ab9484 from Abcam, Hiddenhausen, Germany.
Antibodies used for immunoprecipitation studies were:
human Scl-70 serum (Topogen, Port Orange, FL, USA)
and mAb 1D6 (Novocastra) against topo I and the
rabbit serum CM1 against p53 (Novocastra). Peroxidase-
conjugated aﬃnity puriﬁed antibodies against goat, rabbit,
human and mouse IgG were obtained from Dianova,
Hamburg, Germany or Biomol.
Extraction ofcells, immunoprecipitation and
immunoblot analysis
Total homogenates from 2 10
5 KMV(HR/30) cells
were prepared, subjected to SDS–PAGE (8–15%) and
western blot transfer on Immobilon-P membranes
(Millipore, Bedford, MA, USA) as described (21). Filters
were stained with antibodies in PBS containing 0.2%
Tween-20 and 5% nonfat dried milk, followed by incuba-
tion with peroxidase-conjugated secondary antibodies and
detected by the ECL reagents SuperSignal West Pico
Chemiluminescent Substrate and West Dura Extended
Duration Substrate (Pierce, Rockford, IL, USA). Cellular
lysates for immunoblot analysis were prepared in lysis
buﬀer (50mM Tris, pH 7.4; 150mM NaCl; 2mM
EGTA; 2mM EDTA; 25mM NaF; 25mM b-glyceropho-
sphate; 0.1mM NaV; proteinase inhibitor, Roche Diag-
nostics, Mannheim, Germany) including phosphatase
inhibitor cocktail (Roche) in the experiment shown in
Figure 6B and 100mg of total protein per sample resolved
by SDS–PAGE. Filters were reprobed with antibodies
against actin, tubulin or TBP, or Ponceau stained to con-
trol for loading diﬀerences. Alternatively, signals for a
nonspeciﬁc band served to verify equal loading.
For immunoprecipitation KMV(HR/30) cells were lyzed
24h after electroporation with the indicated plasmids
in 50mM HEPES (pH 7.8), 200mM NaCl, 0.1% Triton
X-100, 20% glycerol and protease inhibitor cocktail
(Roche). For isolation of topo I-Wtp53 complexes
in vivo cross-linking was performed as described in Zink
et al. (26). Centrifuged extracts were precleared with pro-
tein A-sepharose (PAS) for 1h, incubated with anti-topo I
or anti-GAPDH antibodies and PAS for 4h and further
processed as in Restle et al. (12).
Densitometric quantiﬁcation of band intensities was
performed using a ChemImager 5500 with software
(Alpha Imunotech Corporation, San Leonardo, Califor-
nia, USA). Values for the protein of interest were cor-
rected with the values obtained for the corresponding
loading control.
HR-analysis, drugtreatment andknockdown
For the determination of HR frequencies with extrachro-
mosomal plasmid substrate, 10
7 KMV cells were electro-
porated with a total amount of 40mg plasmid DNA
(10mg HR-EGFP/30EGFP, 10mg pCMV-I-SceI, 10mg
pBS, 10mg p53 expression plasmid or empty vector con-
trols). For chromosomal HR measurements, 4 10
6
KMV(HR/30)o r3 10
6 WTK1(HR/30) cells were electro-
porated with 30mg plasmid DNA (10mg pBS, 10mg p53
expression plasmid, cyclin A1 or cyclin A2 expression
plasmid or empty vector controls) with or without 10mg
pCMV-I-SceI. 48–72h after electroporation ﬂow cytom-
etric analysis was performed in a FACS (Becton
Dickinson) to determine the fraction of green ﬂuorescent
cells within a population of nonﬂuorescent cells as
described previously (21). Each measurement was paral-
leled by the same coelectroporation including a WtEGFP
control plasmid instead of a pBS ﬁller plasmid. The
fraction of EGFP-positive cells in these controls was
determined each and was used to normalize each single
recombination frequency. This calculation procedure
also corrects for possible rate deviations related to
growth and death regulatory eﬀects. For drug treatment,
KMV(HR/30) cultures were split and treated with kinase
inhibitor or solvent starting from 4h after electroporation
until measurements were performed (72h). Caﬀeine
(Sigma, Deisenhofen, Germany) was dissolved in H2O
and included at a ﬁnal concentration of 400mM, CGK
(Sigma) in DMSO and applied at 2mM; olomoucine
(Calbiochem) was dissolved in DMSO and added at
80mM. In topo I, p53, WRN, cdk2 and E2F1 knockdown
experiments 20mg of pSUPER-TopoI, pSUPER-p53,
pSUPER-WRN, pKD-cdk2-v5, pKD-E2F-1-v1 or empty
vector were added to the coelectroporation mixture (trans-
fection eﬃciency: 40–80%). The statistical signiﬁcance of
diﬀerences was calculated by use of the t-test.
RESULTS
Changes inthe regulation ofhomologous DSB repair
after mutation ofp53 phosphorylation sites
Recombinative repair represents a well-established direct
DNA repair function of p53 (2,14,15) and had been char-
acterized by use of an EGFP-based assay in K562 derived
KMV cell clones, which are devoid of endogenous
5364 Nucleic Acids Research, 2008, Vol. 36, No. 16p53 (19,21). In this assay, HR between mutated EGFP
sequences, located on the same or the sister chromatid,
restores a functional EGFP gene, which can be monitored
by ﬂow cytometry via quantitation of green ﬂuorescent
cells(Figure1A).DNA-exchangeprocessesaretriggeredby
DSBformationinvivo,whentherare-cuttingmeganuclease
I-SceI is expressed and introduces a single DSB at the
recognition sequence within the repair substrate.
To examine the role of p53 phosphorylation in the
modulation of HR, we chose to express a series of rat
p53 phosphorylation mutants, which in a previous com-
parative study had been shown to retain transcription
activity (7). Thus, we cotransfected KMV(HR/30) cells,
carrying the stably integrated HR-substrate HR-EGFP/
30EGFP (Figure 1A), with expression plasmids for I-SceI
(pCMV-I-SceI) and for Wtp53, oncogenic p53(174Y) or
phosphorylation mutants p53(15A), p53(4/6A), p53(390)
or p53(310/313A), or empty vector. HR was reduced
down to 47% by Wtp53, when compared with the p53-
negative control (P=0.034) (Figure 1B). We found simi-
lar HR repression by the mutants p53(390A) (P=0.012)
and p53(310/313A) (P=0.005). p53(174Y), which is
devoid of any functions in transcriptional and HR regula-
tion (21), showed loss of function. After expression of
p53(15A) or p53(4/6A) minor, statistically not signiﬁcant,
changes in HR frequencies compared to p53-negative con-
trols were noted (P=0.307 and P=0.193, respectively).
When we analyzed p53 expression, we noticed lower levels
for p53(15A) and p53(4/6A) as compared to Wtp53
(Figure 1C). Nevertheless, regarding the products of
genes, which are subject to transcriptional transactivation
or repression by p53, we observed comparable p21
increases in the presence of Wtp53 as well as for
p53(15A), p53(4/6A), p53(390) and p53(310/313A), and
no decrease of RAD51.
Repression of homologous DSB repair byp53 is lost after
ATM/ATR kinase inhibition
Phosphorylation of p53 at serine 15 by ATM and ATR is
thought to initiate the cascade of DNA damage-induced
posttranslational modiﬁcation events on p53 (3,4). To
further delineate a potential role of serine 15 phosphoryla-
tion in the regulation of DSB repair, we cotransfected
KMV(HR/30) cells with pCMV-I-SceI and constructs for
comparable expression of human Wtp53 and the phos-
phorylation mutant p53(15A) (21) (Figure 2C). Wtp53
caused a 36–51% (P=0.017–0.046) decrease of chromo-
somal HR (Figure 2A and B). p53(15A) expressing cells
exhibited an intermediate phenotype with a recombination
frequency reduction of 10–31% (P=0.047–0.517). For
comparison, the HR regulation defective tetramerization
mutant, p53(1-333), caused a statistically not signiﬁcant
25% decrease (P=0.126). To study the possible involve-
ment of ATM and/or ATR, we next treated the cells with
the ATM and ATR inhibitor caﬀeine (27). Western blot
Figure 1. HR analysis after expression of p53 proteins mutated on N- and C-terminal phosphorylation sites. (A) Schematic drawing of the HR assay
substrate HR-EGFP/3’EGFP, which allows to quantify homologous DSB repair by FACS after I-SceI-mediated cleavage (21). (B) KMV(HR/3’) cells
were electroporated with pCMV-I-SceI, and pKEX (control) or pKEX derivatives for the expression of Wt and mutant (174Y, 15A, 4/6A, 390A,
310/313A) p53 from rat, and cultivated for 72h. Recombination frequencies were determined as the fraction of green ﬂuorescent cells compared to
the total cell population and normalized in each case to the individual transfection eﬃciency. Columns, mean (n=6); bars, SEM. (C) Total cell
homogenates were prepared from transfected KMV(HR/3’) cells and the amounts of p53, p21 and RAD51 were analyzed by immunoblotting.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5365analysis veriﬁed reduced phosphorylation of p53 at serine
15 after caﬀeine treatment (Figure 2C). Caﬀeine treatment
completely abrogated HR-repression by Wtp53 as well as
the residual inﬂuence by p53(15A) and p53(1-333)
(Figure 2A).
To rule out a major contribution of the cell cycle to
the eﬀects shown in Figure 2A, we analyzed by ﬂow cyto-
metry the cellular distribution of G1-, S- and G2-phases.
Under the conditions of HR measurements (72h treat-
ment with 400mM caﬀeine, purposefully chosen after titra-
tion analysis to exclude cytotoxic eﬀects), all cell types,
with or without p53 expression and with or without inhib-
itor treatment, showed comparable cell-cycle proﬁles
(Supplementary Figure 1A). In addition, the fraction
of apoptotic cells identiﬁed by sub-G1 DNA content
after propidium iodide staining, was neither signiﬁcantly
diﬀerent in this experiment nor in the experiments
described below (Supplementary Figure 1B and data not
shown). This is in agreement with the fact that K562
cells are defective in apoptosis induction after p53 expres-
sion (28). Since RAD51 was demonstrated to represent
the immediate target of p53-dependent HR inhibition
(2,14,15), we wished to compare the inﬂuence of Wtp53
with inactivation of RAD51. For that purpose, we
expressed SMRAD51, a yeast–mouse chimera, with a
dominant-negative eﬀect but which does not modify cell
viability in mammalian cells (24). We found repression
of DSB-induced HR in KMV(HR/30) cells down to 63%
(P=0.001), i.e. to a degree similar to that of Wtp53. This
is compatible with p53 exerting its anti-recombinogenic
eﬀect via inhibition of RAD51-dependent HR pathways
such as gene conversion (21,29).
Additionally, when we tested the more potent and selec-
tive ATM/ATR inhibitor CGK (30), which also caused
reduced phosphorylation of p53 at serine 15 (Figure 2C),
we again observed loss of HR repression by Wtp53 and no
further change for p53(15A) (Figure 2B). Altogether, our
ﬁndings suggest that serine 15, which is phosphorylated by
ATM and ATR, is required for fully eﬃcient regulation
of DSB-induced HR. They also show that cellular ATM
and/or ATR kinase activities are needed to uncover
diﬀerences in HR frequencies between p53-positive and
-negative cells.
Stimulation of I-SceI-independent HR by p53requires
the cdk phosphorylation site,serine 315
Given that mutation of phosphorylated amino acids on
the C-terminus of rat p53 did not alter DSB repair regula-
tion (Figure 1B), we conﬁrmed these observations for
human p53. Therefore, we performed HR measurements
on chromosomally integrated substrates after expression
of human Wtp53 and cancer-related mutant p53(273H),
p53(315A), p53(392A) and p53(392D). p53(315A) and
p53(392A) are resistant to phosphorylation on the respec-
tive serine, whereas p53(392D) mimics phosphorylation
on serine 392. p53(315A), p53(392A) and p53(392D)
downregulated homologous DSB repair similar to Wtp53
(P 0.001) (Figure 3A). For comparison, p53(273H)
showed residual chromosomal downregulation activity,
however, without statistical signiﬁcance (P=0.096).
Protein levels of p21 were comparably elevated in Wtp53,
p53(315A), p53(392A) and p53(392D), but not p53(273H)
producing cells, whereas RAD51 protein levels remained
constant (Figure 3B). Thus, phosphorylation of serines 315
Figure 2. Inﬂuence of ATM/ATR-mediated phosphorylation. (A) Homologous DSB repair of chromosomal substrates was assayed in KMV(HR/30)
cells as in Figure 1 using the following expression plasmids for human p53 fused to the human estrogen receptor hormone-binding domain:
pSVp53her (Wt), pSVp53(15A)her, pSVp53(1-333)her or pBS (control) in the absence or presence of 400mM caﬀeine (A)o r2 mM CGK (B).
Recombination frequencies in cells without p53 were set to 100% [absolute mean value in (A) and (B): 1.0 10
 3]. Columns, mean (n=3–9);
bars, SEM. (C) Equal expression of p53her and p53(15A)her and decreased phosphorylation of p53her at serine 15 after caﬀeine and CGK
treatment, respectively.
5366 Nucleic Acids Research, 2008, Vol. 36, No. 16and 392 does not play a signiﬁcant role in p53-mediated
repression of DSB-induced HR.
Since amino acid 315 is located within the topo
I-binding site of p53 (31), we next sought to determine
the involvement of serine 315 in the stimulation of
I-SceI-independent HR, which was shown to be mediated
by Wtp53 and topo I (19). HR was monitored using
KMV(HR/30) cells in combination with expression of
human Wtp53, p53(315A), or the hotspot mutants,
p53(273H) and p53(248W), in the absence of substrate
cleavage by I-SceI. Consequently, we scored an average
recombination frequency two orders of magnitude below
I-SceI-induced HR (see legend to Figure 4A and B).
I-SceI-independent HR was increased  2-fold by Wtp53
(P=0.023), p53(273H) (P=0.113) and p53(248W)
(P=0.001), but not by p53(315A) (Figure 4A). To deter-
mine, whether HR enhancement is topo I-dependent,
we repressed endogenous topo I expression by transfect-
ing with pSUPER-TopoI (19) (Figure 5D). In these
knockdown assays, HR stimulation was abolished for
Wtp53, p53(273H) and p53(248W), reaching statistical
signiﬁcance for Wtp53 (P=0.030) and p53(248W)
(P 0.001). To exclude the possibility that topo I repre-
sents an essential component of HR, we performed the
same HR measurements with simultaneous I-SceI expres-
sion for targeted substrate cleavage. Under these condi-
tions, topo I knockdown had no eﬀect on HR activities,
regardless of the p53 status (Figure 4B). FACS analysis of
the fraction of cells with G1, S or G2 DNA content or of
apoptotic cells failed to detect signiﬁcant diﬀerences
between samples without and with expression of Wtp53,
p53(273H) or p53(248W), arguing against HR stimulation
being indirectly caused by the classical tumor suppres-
sor activities (Supplementary Figure 1B). These results
indicated that both Wtp53 and oncogenic mutant p53
stimulate I-SceI-independent HR, topo I-mediated recom-
bination and revealed that serine 315 is essential for the
stimulatory eﬀect.
Oncogenic p53 mutants stimulate cyclin A1-induced,
topoI-dependent homologous DSB repair
Cyclin A1, an alternative, cdk2 associated A-type cyclin,
has been linked to DSB repair, and its promoter repre-
sents a transcriptional transactivation target of p53 (23).
Figure 3. HR regulation upon mutation of C-terminal p53 phosphorylation sites. (A) Chromosomal homologous DSB repair using human p53
expression plasmid pCMV-p53(273H), pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(392A), pCMV-p53(392D) or empty vector (control). Recom-
bination frequencies in cells without p53 were set to 100% (absolute mean value: 2.0 10
 3). Columns, mean (n=6–12); bars, SEM. (B) Western
blot analysis of p53, RAD51 and p21.
Figure 4. p53-mediated regulation of HR after knockdown of topo I. (A) and (B) KMV(HR/30) cells were transfected with pCMV-Wtp53, pCMV-
p53(315A), pCMV-p53(273H), pCMV-p53(248W) or empty vector (control) and pSUPER ( ) or pSUPER-TopoI (+) for topo I-speciﬁc RNA
interference, and subjected to HR-measurements. For I-SceI-mediated substrate cleavage in (B), pCMV-I-SceI was included in the transfection
mixture. Recombination frequencies of p53-negative cells with pSUPER were set to 100% (absolute mean values: 2.7 10
 5 without I-SceI and
2.0 10
 3 with I-SceI). Columns, mean values of 12 to 41 (A) and six (B) measurements, respectively; bars, SEM.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5367To test a potential contribution of cyclin A1 in the regula-
tion of homologous DSB repair by p53, we simultaneously
expressed cyclin A1, p53 proteins and I-SceI in KMV
(HR/30) cells. In parallel, we examined the inﬂuence
of cyclin A2. We found a 69–83% enhancement of homo-
logous DSB repair after cyclin A1 expression in cells with
p53(273H) (P 0.004) and of 65–148% for p53(248W)
(P 0.006), whereas in p53-negative controls frequencies
were only 7–18% higher (P>0.05) (Figures 5A, 6A and
7A). In cells expressing mutant p53(175H), we measured
78% higher HR frequencies (P=0.013). After cyclin A2
expression, relative increases were 47–83% for p53(273H)
Figure 5. Eﬀect of cyclin A1 and A2 on homologous DSB repair in cells diﬀering in their p53 and topo I status. (A) DSB-induced HR was
determined in KMV(HR/30) cells cotransfected with pCMV-I-SceI, and pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(273H), pCMV-p53(248W) or
empty vector (control), and pcDNA3-cyclin A1 (A1), pCMV-cyclin A2 (A2) or empty vector ( ). Columns, mean (n=12–27); bars, SEM. (B) DSB-
induced HR in cells overexpressing cyclin A1, cotransfected with pSUPER ( ) or pSUPER-TopoI (+). Columns, mean (n=12–18); bars, SEM. (C)
DSB-induced HR in cells overexpressing cyclin A2, cotransfected with pSUPER ( ) or pSUPER-TopoI (+). Columns, mean (n=6); bars, SEM.
Recombination frequencies in controls were set to 100% (absolute mean value in (A)  p53/ cyclins: 2.1 10
 3; in (B)  p53/+cyclin A1/ pSUPER-
TopoI: 2.2 10
 3; in (C)  p53/+cyclin A2/ pSUPER-TopoI: 2.8 10
 3). (D) pSUPER-TopoI-mediated downregulation of topo I protein com-
pared to p53 expression. (E) Western blotting of cyclin A1 and cyclin A2.
5368 Nucleic Acids Research, 2008, Vol. 36, No. 16(P=0.009–0.025), 42–60% for p53(248W) (P=0.003–
0.014), and 35–49% for controls (P 0.019). As expected,
in cells with Wtp53 and p53(315A), DSB-induced HR was
strongly suppressed, namely on average to 20% of control
levels (Figure 3A), with increments of 35–41% and 17–
33% upon cyclin A1 and of 13–48% and 46–47% upon
cyclin A2 production (P>0.05), respectively (Figures 5A,
6A and 7A). Flow cytometric analysis revealed that cells
expressing cyclin A1 or cyclin A2 showed similar cell-cycle
distributions compared with controls (Supplementary
Figure 1C). Moreover, we measured recombination in
the presence of the pancaspase inhibitor zVAD-fmk
(50mM) for Wtp53, p53(315A) and p53(273H) versus con-
trol (  cyclin A1 each). Recombination results did not
diﬀer from the initial results, thus, arguing against an
involvement of apoptosis in the HR regulation (data not
shown).
We noticed that exogenous p53(273H) exerted residual
HR-repression activities to a varying extent (Figures 5A,
6A and 7A) (21,32). Therefore, we wished to compare
cyclin A1-mediated HR stimulation in cells stably expres-
sing endogenous mutant p53 and cell derivatives with-
out p53. Consequently, we analyzed HR activities in the
human B-lymphoblastoid cell line WTK1(HR/30) carrying
p53(237I) (21) and chromosomally integrated HR
Figure 6. Inﬂuence of cdk inhibition on HR regulation by cyclin A1 and mutant p53. (A) DSB-induced HR in KMV(HR/30) cells treated with
DMSO ( )o r8 0 mM olomoucine (+). Recombination frequencies in controls  p53/ cyclin A1/ olomoucine were set to 100% (absolute mean
value: 1.1 10
 3). Columns, mean (n=12–18); bars, SEM. (B) Immunoblot analysis for p53pSer315 and p53. (C) Cell-cycle analysis. Columns, mean
(n=2); bars, SD.
Figure 7. Regulation of HR by cyclin A1 and mutant p53 after
knockdown of cdk2. (A) DSB-induced HR in KMV(HR/30) cells
cotransfected with empty vector or pKD-cdk2-v5 (pKD-cdk2) for
cdk2-speciﬁc RNA interference. Recombination frequencies in controls
 p53/ cyclin A1/ pKD-cdk2 were set to 100% (absolute mean value:
1.2 10
 3). Columns, mean (n=6); bars, SEM. (B) Western blot anal-
ysis of cdk2.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5369substrate. HR assays were performed with and without
cyclin A1 overexpression and concomitantly with or with-
out knockdown of endogenous p53 by pSUPER-p53
(Supplementary Figure 2B). This approach revealed a
statistically signiﬁcant (25%, P=0.001) rise in HR fre-
quencies from mutant p53-deﬁcient (+ pSUPER-p53)
to -proﬁcient cells (+pSUPER) only after cyclin A1 over-
expression (Supplementary Figure 2A). Cell-cycle changes
were not observed (Supplementary Figure 2C).
We next reapplied pSUPER-TopoI to analyze the invol-
vement of topo I in the cyclin A1 and cyclin A2-dependent
stimulation of homologous DSB repair. Interestingly,
after topo I knockdown in KMV(HR/30) cells we did
not ﬁnd signiﬁcant diﬀerences in HR frequencies except
for the cells expressing cyclin A1 in combination with the
oncogenic p53 mutants (Figure 5B and C). Thus, with
p53(273H) HR was reduced by 28% (P=0.004), with
p53(248W) by 43% (P=0.001). We veriﬁed topoisom-
erase downregulation as depicted in Figure 5D for cultures
with and without cyclin A1 expression. In the same sam-
ples, p53 levels did not follow the topo I expression pat-
tern when compared to the TBP control. Taken together,
both cyclin A1 and cyclin A2 overexpression (Figure 5E)
caused an enhancement of DSB-induced HR, particularly
in cells expressing a p53 hotspot mutant. When compared
to p53-negative controls, mutant p53-mediated HR stimu-
lation was much more pronounced in cells with cyclin A1
rather than cyclin A2. This indicated a cyclin A1- and
mutant p53-speciﬁc component. Most importantly, HR
enhancement was abolished by topo I knockdown solely
in cells with cyclin A1 and mutant p53.
Mutantp53-mediated stimulation of homologous
DSB repairrequires cdk2
We next used two independent approaches to analyze the
role of cdk2 in regulating HR after cyclin A1 and mutant
p53 expression. First, we included the cdk inhibitor, olo-
moucine, into KMV(HR/30) cultures after transfection
with I-SceI, cyclin A1, and p53 expression plasmids.
Olomoucine treatment abolished the recombination sti-
mulatory eﬀect of cyclin A1 in mutant p53 expressing
cells (Figure 6A; P 0.016). Unexpectedly, in p53-
negative controls, HR enhancement by cyclin A1 was
more pronounced after drug treatment. Without cyclin
A1 expression, no signiﬁcant diﬀerences were observed
between any of the mock- and olomoucine-treated sam-
ples (Figure 6A). Immunoblotting veriﬁed the eﬀective-
ness of the cdk inhibitor, because signals speciﬁc for
p53 phosphorylated on serine 315 were reduced down
to 37–51% after olomoucine treatment in p53(248W)
samples, although total levels of p53 remained unaltered
(Figure 6B). Phosphorylation of serine 315 in Wtp53 was
aﬀected to a lesser extent (64–100% residual levels) and
additionally accompanied by a decrease in total p53 levels.
Flow cytometric analysis did not reveal major changes in
cell cycle distribution for p53-positive cells (Figure 6C).
However, for p53-negative cells expressing cyclin A1, we
noticed that the percentage of cells residing in S-phase rose
from 20% to 38% in response to olomoucine treatment,
which was consistent with observations previously
made in breast cancer cells (33). Considering that cells
are highly active in HR during S-phase (34), cell cycle
regulatory eﬀects may underly the unexpected HR
increase that we observed in treated, cyclin A1 expressing,
p53-negative cells.
In the second experimental setup, we examined
DSB-induced HR after cdk2 knockdown. As depicted in
Figure 7A, downregulation of cdk2 (Figure 7B) in assays
with cyclin A1 and p53(273H) or p53(248W) signiﬁcantly
reduced HR frequencies to levels without cyclin A1
(P=0.000, P=0.014, respectively). Although corre-
sponding mean values for p53-negative controls also indi-
cated a HR decrease, statistical signiﬁcance was not
reached (P=0.066). Cell-cycle proﬁles did not show
major diﬀerences after cdk2 knockdown (Supplementary
Figure 1D). We further tested a possible involvement of
E2F1 in the cyclin A1- and mutant p53-dependent HR
stimulation, since nuclear retention of p53 by the trans-
cription factor E2F1 was reported to require phosphory-
lation of p53 at serine 315 (35) and since cyclin A1 was
shown to bind to E2F1 (36). In addition, we checked the
inﬂuence of Werner’s syndrome protein (WRN), which
was described to bind both p53 (37) and topo I (38,39).
Recently, Song et al. (40) reported that mutants
p53(248W) and p53(273H) displayed tumor-promoting
characteristics in a humanized p53 knockin mouse model
and caused genetic instability by inactivating ATM signal-
ing of DSBs. Consequently, we also examined links to
ATM. However, unlike the situation observed after
olomoucine treatment or cdk2 knockdown, neither
downregulation of E2F1, WRN or ATM nor caﬀeine
treatment reversed recombination enhancement mediated
by cyclin A1 and mutant p53 (data not shown). In sum-
mary, cdk2 inactivation by pharmacological inhibition or
RNA interference suppressed the HR-stimulatory eﬀect of
mutant p53, which suggests that phosphorylation by
cyclin A1-cdk2 is a critical step in this process.
Cyclin A1 stimulates association of topoI withp53
Given that cyclin A1-mediated stimulation of homolo-
gous DSB repair depends on topo I and mutant p53,
we examined whether formation of protein complexes
containing oncogenic mutant p53 and topo I is involved
in cyclin A1-mediated recombination stimulation. For this
purpose, we performed coimmunoprecipitation analysis
using Scl70-antiserum, which had previously been estab-
lished for speciﬁc precipitation of topo I complexes (41).
Topo I-bound proteins were recovered from extracts of
cells transfected and treated for DSB-repair measurements
as in Figure 6. p53(248W) bound to topo I, particularly
in cells overexpressing cyclin A1 (Figure 8). Under these
conditions, we were unable to detect Wtp53 signals in topo
I precipitates, unless chromatin complexes were cross-
linked in vivo (Figure 8), indicating weak or transient
interactions with topo I. Additional treatment of these
cells with olomoucine reduced the association of Wtp53
and particularly of p53(248W), with topo I, supporting the
hypothesis that cyclin A1/cdk-mediated phosphorylation,
plays an important role in the stable association of onco-
genic p53 with topo I.
5370 Nucleic Acids Research, 2008, Vol. 36, No. 16DISCUSSION
The p53 is phosphorylated on several residues in response
to genotoxic stress, in particular to insults such as DSBs
(2,4,15). Because of the well-established regulatory func-
tions of p53 in DSB repair pathways, we and others pre-
viously proposed that damage-induced phosphorylation
may modulate repair-related p53 activities. In this study,
we systematically examined this hypothesis, demonstrat-
ing that phosphorylation of p53 at diﬀerent positions
modulates distinct DNA repair-related functions of p53.
Functional proof of apartial involvement ofserine 15
in DSB repair
Phosphorylation of p53 at serine 15 by ATM represents
the initial p53 modiﬁcation induced by DSBs (4). In chro-
matin immunoprecipitation experiments ATM and p53
were found to localize to DSBs preceding repair (42).
Moreover, we and others previously demonstrated that
p53pSer15 represents the p53 subpopulation colocalizing
with the MRE11 complex, RAD51 and RAD54 after
replication blockage (11–13). However, so far, only indi-
rect evidence suggested HR-related functions for this sub-
population of posttranslationally modiﬁed p53. In this
work, we demonstrate that serine 15 of p53 is necessary
for fully eﬃcient repression of homologous DSB repair.
On the other hand, with C-terminal phosphorylation site
mutants, changes in HR downregulation were not detect-
able. We noticed that the phosphorylation-resistant
mutant p53(15A) displayed residual HR-repression activ-
ities, whereas chemical inhibition of ATM and ATR com-
pletely abrogated p53-dependent HR downregulation.
This can be explained by the involvement of additional
N-terminal sites which, like serines 20 and 37, are directly
or indirectly modiﬁed after ATM/ATR activation (3,4).
However, we cannot exclude that ATM and/or ATR are
required for p53-mediated HR repression independently
of p53 phosphorylation.
Under the conditions of the DSB repair test, we
observed no alterations in transcriptional transactivation
nor in repression by p53(15A), when monitored via p21
and RAD51 expression. Additionally, we largely excluded
that the inﬂuence of serine 15 phosphorylation on HR was
caused by major p53 activities in cell cycle control or
apoptosis induction. Our observations strengthen earlier
conclusions of a direct involvement of p53 in RAD51-
dependent gene conversion (2,14,15). Physical interactions
with heteroduplex DNA recombination intermediates
and RAD51 do not involve the N-terminus of p53 (15).
RPA binding, which like RAD51 binding is required for
HR repression by p53, was mapped around aa 48–54, and,
therefore, is more likely to be modulated by N-terminal
phosphorylation (43). Importantly, colocalization and
immunoprecipitation experiments showed that BLM facil-
itates physical interactions between p53 and the sensor
proteins 53BP1 and H2AX, and thereby leads to eﬃcient
localization of p53 to RAD51 foci and to a net increase
in p53pSer15 (11,44). Therefore, phosphorylation of
N-terminal p53 amino acids by ATM, ATR and down-
stream kinases may stabilize one or multiple contacts
with recombination factors, enabling the HR repression
function of p53.
Linksbetween p53 and cyclin A1in recombination
Consistent with our previous observations (18,19), we
showed here that Wtp53 activates HR in the absence of
targeted substrate cleavage in a topo I-dependent manner.
We have now discovered the same to be true for the
hotspot mutants p53(273H) and p53(248W). Serine 315
turned out to be necessary for topo I-dependent HR
stimulation, whereas it was dispensable for the repression
of DSB-induced HR.
Cyclin A-cdk2 was previously shown to phosphorylate
serine 315 of human p53 (45,46). Interestingly, we found
that even DSB-induced HR was stimulated by mutant
p53 in a manner depending on topo I, when cyclin A1
was overexpressed (up to 20-fold further increase as
compared to the p53-negative control). Under the same
conditions, Wtp53 caused repression of homologous
Figure 8. Coimmunoprecipitation of topo I and p53 is enhanced by cyclin A1. KMV(HR/30) cells were electroporated with pCMV-I-SceI plus empty
expression vector (control), pCMV-p53(248W) or pCMV-Wtp53 plus empty vector or pcDNA3-cyclin A1, and treated with DMSO ( )o r8 0 mM
olomoucine, exactly as described in Figure 6. Twenty-four hours later, whole-cell extracts were prepared without [p53(248W)] or with (Wtp53) cross-
linking of chromatin complexes in vivo and topo I immunoprecipitated with Scl-70 serum followed by western blotting for p53 or topo I. As a
negative control for nonspeciﬁc topo I interactions, the extract was immunoprecipitated with anti-GAPDH antibodies (IgG). Nonspeciﬁc signals in
the western blot from the heavy chain with a molecular mass similar to p53 were excluded by the empty vector controls.
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cyclin A2 was accompanied by a mostly p53- and topo
I-independent increase in homologous DSB repair. This
general increase in HR is in line with a report describ-
ing that eﬃcient DSB-induced ATM/ATR-signaling to
Chk1 requires cdk kinase activity (47). Since Chk1
is required for RAD51 activation, this implies that cdks
promote HR (48).
From our data and given that cyclin A1 is a target gene
product of Wtp53 (23), we would like to put forward the
following hypothesis (Figure 9): WTp53 may support
rare HR processes via cyclin A1 and topo I in normal,
proliferating cells, particularly during S-phase, when
active DNA synthesis is associated with replication fork
stalling and recombinative bypass events. However, in
the presence of severe damage such as DSBs, ATM-
signaling may dominantly promote HR-repression func-
tions of Wtp53, i.e. overcome HR stimulation. Oncogenic
mutant p53 has lost the HR repression but retained the
HR-stimulation function resulting in a net increase of
recombination.
Dynamic p53-topoI interactions as themechanistic basis
ofcyclin A1-induced recombination
Topo I is known to bind p53 between aa 302 and 321 (31),
i.e. in a region containing serine 315, which is phosphory-
lated in response to cyclin A1 expression. Immunopreci-
pitation experiments revealed that overexpression of
cyclin A1 promoted physical interactions between topo I
and p53(248W). For Wtp53, we noticed comparatively
weak or transient topo I binding, which is in agreement
with observations made by Gobert et al. (31). Cyclin
A1-enhanced p53–topo I interactions were reduced
after pharmacological inhibition of cdks, particularly
for p53(248W). Thus, we propose that cyclin A1/cdk2-
mediated phosphorylation of p53 enables stable complex
formation with topo I, thereby causing hyper-recombina-
tion in p53 mutant cells (Figure 9).
Topo I has been recognized as a DNA metabolizing
enzyme that—once localized to DNA lesions by other
proteins—is necessary for the recruitment of DNA
repair enzymes. On the other hand, topo I is potentially
dangerous due to its nicking–closing activity (49). Topo I
facilitates initiation of genetic recombination through
strand breakage after strand pairing and/or resolution of
DNA junctions (50–52). p53, and oncogenic mutant p53
in particular, was previously demonstrated to stimulate
topo I relaxation activity (31,53,54) and the formation
of topo I double cleavage complexes causing oligonucleo-
tide excision coupled to recombinative gap ﬁlling (55).
From this, it is conceivable that stable complex formation
between topo I and mutant p53 after cdk-mediated p53
phosphorylation is suﬃcient to inappropriately stimulate
recombinase activities through recruitment to genomic
DNA breaks and enzymatic activation of topo I.
Gain-of-function inp53 mutants and genome destabilization
It has been well-established that cancer-related p53
mutants, including p53(273H) and p53(248W), not only
lost tumor suppressor functions, but also acquired addi-
tional oncogenic activities (56). In this study, we utilized
cellular systems derived from p53-negative or mutant p53
cells to exclude dominant negative eﬀects on endogenous
Wtp53. p53 gain-of-function eﬀects on genomic instabil-
ity, in particular, are manifested by aberrant ploidy,
increased mutation and gene ampliﬁcation rates (56–58).
We and others proposed that topo I mediates gain-
of-function of mutant p53 (18,31,41,54). To our knowl-
edge this is the ﬁrst report that demonstrates that cyclin
A1 stimulates DSB-triggered HR in cells that express
mutant p53 but not in cells lacking p53, which indicates
a gain-of-function. This eﬀect is mediated by cdk2-
dependent phosphorylation and by topo I. Cyclin A1
Figure 9. Proposed model of a cyclin A1-induced mechanism leading to genomic instability by oncogenic mutant p53.
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even when directly comparing HR frequencies in cells with
versus without mutant p53. This was evident after knock-
down of endogenous mutant p53 (Supplementary
Figure 2).
Increased topo I activities were detected in several cancer
types and found to correlate with abnormal p53 function
in melanomas (49). Since mutant p53 is transcriptionally
defective, it is important to note that p53 is not the only
regulator of cyclin A1 expression. Rather, upon mutation
of TP53, alternative transcription factors, such as the
oncoproteins c-myb, Six1 and PML-RARa, can induce
cyclin A1 expression (59–61). In fact, elevated cyclin A1
levels have been detected in several cancers including male
germ cell tumors (62), breast cancer (61) and in acute mye-
loid leukemia (63), whereas it is normally suppressed in
most somatic cells (Figure 9). Evidence for the important
role of cyclin A1 in the initiation of acute myeloid leukemia
was provided by a transgenic mouse model with targeted
cyclin A1 in the bone marrow (64). Most intriguingly, with
respect to the observed synergistic eﬀect of mutant p53 and
cyclin A1 on recombination, Tokumaru and colleagues
(65) found a negative correlation between cyclin A1 hyper-
methylation, with robust cyclin A1 protein expression and
p53 mutation in head and neck cancer. From our results,
mutant p53 is predicted to promote genome instability in
tumors with cyclin A1 overexpression.
In summary, we have demonstrated that phosphoryla-
tion of p53 at distinct amino acids does diﬀerentially
regulate direct DNA repair-related activities. We provide
functional data, which unveil a role of the ATM/ATR-
target serine 15 in fully enabling p53 to downregulate
HR and of cdk2-dependent phosphorylation in activating
HR. Phosphorylation of p53 at serine 15 forms part of the
ATM/ATR-controlled DNA damage response network,
which is activated early in tumorigenesis before genomic
instability occurs (66,67). p53Ser15 may, therefore, contri-
bute at least in part through repair regulatory functions to
the barrier against cancer, and indeed, recent in vivo data
demonstrate that serine 15 is required for p53-mediated
tumor suppression (68). On the other hand, we provide
evidence that oncogenic p53 mutant proteins have lost
the balance between activation and repression of recombi-
native repair, which under conditions such as cyclin A1
overexpression may result in an increase of mutagenic
DNA rearrangements such as gene ampliﬁcation or loss
of heterozygosity. Our data provide new answers to the
longstanding question of the mechanism underlying the
gain-of-function in oncogenic p53 mutants in genome
instability.
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